In this episode of the Beasley Allen Report, host Gibson Vance welcomes fellow Beasley Allen principal David Byrne to speak on a relatively new and dangerous blood thinner on the market, Xarelto.
Xarelto is in a new class of blood thinners designed to be an alternative to warfarin for the treatment of blood clots; however, unlike warfarin, there is no antidote to reverse the blood thinning effects. Despite being approved by the FDA, Xarelto carries many black box warnings, the most serious kind issued by the FDA. The warnings link the drug to an increased risk of blood clots with premature discontinuation of therapy, and a risk of epidural or spinal hematomas resulting in long-term or permanent paralysis in patients treated with Xarelto receiving neuraxial anesthesia or undergoing spinal puncture. Byrne recommends talking to your doctor if you are already taking Xarelto in order to have an honest discussion about concerns and alternative options.
For more information on Xarelto and the firm’s latest legal news, visit Beasley Allen’s website at www.BeasleyAllen.com.